Wells Fargo raises Ultragenyx Pharma price target on phase 3 data
Covered in this story
What has happened since
- Wells Fargo is down 4.5% since this was published, 48 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Wells Fargo
- Citi: $80.7 → $88 by Oct 2027 · Neutral via MarketBeat
- RBC Capital Markets: $79.9 → $92 by Oct 2027 · Outperform via TradingView
- TD Cowen: $81.6 → $95 by Oct 2027 via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $WFC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Wells Fargo →Dalsna Finance is currently tracking 60 stories mentioning Wells Fargo, the earliest published 5 Aug 2026.
Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.